Fortress Biotech, Inc.
NASDAQFortress Biotech heads into its Q1 2026 print with one of the most elevated short positioning profiles among small-cap biotechs. Short sellers are heavily committed. At 14.6% of free float, short interest is material and has climbed roughly 14% over the past month — even as it eased slightly over the last week, slipping 5.5% from its peak. The ORTEX short score has been locked near…
Snapshot as of 15 May 2026
Fortress Biotech heads into its Q1 2026 print with one of the most elevated short positioning profiles among small-cap biotechs. Short sellers are heavily committed. At 14.6% of free float, short interest is material…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for FBIO — free to start on ORTEX.
Sign up for free →Open FBIO on ORTEX